| Assessment Status | Rapid Review Complete |
| HTA ID | 24050 |
| Drug | Spesolimab |
| Brand | Spevigo® |
| Indication | Spesolimab is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy. |
| Assessment Process | |
| Rapid review commissioned | 06/12/2024 |
| Rapid review completed | 19/12/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of spesolimab compared with the current standard of care. |
